🎥 A Soaring Biotech With an Impressive 34% CROCI

And that's not all there is to like...‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

New to the Digest? Click here. Stocks Gold Crypto Trading Academy Stock of the Week: A Soaring Biotech With an Impressive 34% CROCI 20X Bigger Than Big Tech? Forget Coins... Tokens... and Crypto Funds... This Tiny Crypto STOCK Could Dominate the Stock Market in 2022. Click Here to Discover Why Alpesh Patel Trading Champion There aren't many stocks that have gone up in 2022. But our latest Stock of the Week has... after nearly doubling last year. It's a biotechnology company that's addressing the huge and growing need to treat chronic diseases as our population ages. It's seen some big gains over the past few years... [Click to Watch - The Secret to an 83% Win Rate...] But even better... it has an impressive 34% CROCI (cash return on capital invested). Find out which stock hits the mark for my Growth-Value-Income system this week... It's all in the latest episode of Stock of the Week. Click here or on the image below to watch it. CLICK HERE TO WATCH Happy hunting, Alpesh P.S. Thank you to everyone who has sent in tickers for me to review. Keep them coming to mailbag@manwardpress.com. And be sure to let me know how you're enjoying this series. SPONSORED "The Lifeblood of the New Economy" Is in Her Hand... Over the next decade, the technology in her hand could create as many as 4.6 million jobs... Contribute up to $1.7 trillion to U.S. GDP... And help some people accrue life-changing wealth. Here's how you could become one of them...   Want more content like this? YES NO   Alpesh Patel | Trading Champion Alpesh Patel is an award-winning hedge fund and private equity fund manager, international bestselling author, and entrepreneur. He is the founder and CEO of Praefinium Partners, a Financial Times top FTSE 100 forecaster, and a senior Dealmaker in the U.K.'s Department for International Trade. As a recognized authority on fintech, online trading and venture capital, his past and current client list includes American Express, Merrill Lynch HSBC, Charles Schwab, Goldman Sachs, Barclays... and more.   Was this email forwarded to you? Click here to sign up! You are receiving this email because you subscribed to Manward Financial Digest. To unsubscribe from Manward Financial Digest, click here. Need help with your account? Click here. Have a question or comment for the editor? Click here. Please do not reply to this email as it goes to an unmonitored inbox. To cancel by mail or for any other subscription issues, write us at: Manward Press, LLC | Attn: Support Team | 14 West Mount Vernon Place | Baltimore, MD 21201 North America: 1.800.682.5210 | International: +1.443.353.4263 Website | Privacy Policy Keep the emails you value from falling into your spam folder. Whitelist Manward Financial Digest. © 2021 Manward Press, LLC | All Rights Reserved Manward Press, LLC is a financial publisher that does not offer any personal financial advice or advocate the purchase or sale of any security or investment for any specific individual. Members should be aware that investment markets have inherent risks and there can be no guarantee of future profits. We expressly forbid our writers from having a financial interest in their own securities recommendations to readers. All of our employees and agents must wait 24 hours after online publication or 72 hours after the mailing of printed-only publications prior to following an initial recommendation. Any investments recommended by Manward Press, LLC should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. The information found on this website may only be used pursuant to the membership or subscription agreement and any reproduction, copying or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of Manward Press, LLC, 14 West Mount Vernon Place, Baltimore, MD 21201.